We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Anticancer Drug Derived from Blue-Green Algae

By Biotechdaily staff writers
Posted on 28 Feb 2008
A collaborative team of researchers has identified a potent new anti-cancer drug isolated from a toxic blue-green algae found in the South Pacific. More...


The properties of somocystinamide A (ScA) were recently described in an article published online in the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) the week of February 11-15, 2008. "We are excited because we have discovered a structurally unique and highly potent cancer-fighting compound,” said Dr. Dwayne G. Stupack, associate professor of pathology at the Moores University of California, San Diego (UCSD) Cancer Center (USA). "We envision it will be perfect for emerging technology, particularly nanotechnology, which is being developed to target cancerous tumors without toxic side effects.”

The ScA compound was found in the cyanobacteria Lyngbya majuscula, also known as "mermaid's hair,” collected off the coast of Fiji in the South Pacific by the laboratory of William Gerwick at Scripps Institution of Oceanography. A diverse team of researchers from UCSD's Cancer Center, and other institutions worked to identify, screen, and test marine compounds in vitro and in vivo. They found that ScA suppresses neovascularization, the formation of blood vessels that feed tumors, and had a direct impact on tumor cell proliferation.

"The compound isn't toxic to the cyanobacteria itself, but activates a ‘death pathway,' present in our cells,” said Dr. Stupack. "When the cells of the blood vessels that feed tumors become activated and proliferate, they become especially sensitive to this agent.” Dr. Gerwick noted that if a normal-sized swimming pool full of cancer cells were treated with ScA, it would take only 3 mg, about the weight of a grain of rice to kill all of the cancer cells.

Wolf Wrasidlo, Ph.D., senior project scientist at the Moores UCSD Cancer Center and first author of the study, added that the unique structure of this compound lends itself very well to nanotechnology, because it "incorporates spontaneously” into molecule-sized nanoparticles, important for the kind of highly targeted, combination therapy being developed to treat cancer. The structure is also simple enough that the scientists can reproduce it.

"ScA is the first, and most potent compound we've identified so far,” Dr. Stupack said, adding that it will not be the last, as the team has identified more than 250 unique compounds from L. majuscula alone. "But we don't yet know how abundant ScA is, or if it's feasible to harvest, so it is important that we have been able to produce this natural product in the lab.”


Related Links:
Rebecca and John Moores UCSD Cancer Center

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.